HIV patients may ditch combo therapy for One-Pill option, study finds
NCT ID NCT00421551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether HIV patients with long-term viral suppression could switch to a single boosted drug (darunavir/r) instead of staying on a standard combination of drugs. 225 adults with well-controlled HIV took part. The goal was to see if the single-drug approach could keep the virus undetectable for 48 weeks. The results help doctors understand if simpler treatment is safe and effective for some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service des maladies infectieuses et tropicales Hopital Pitie salpetriere
Paris, 75013, France